Minerva Neurosciences (NERV) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Protara Therapeutics (TARA) over the past year, gaining 13.8% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -70.2% for NERV. Protara Therapeutics is the larger company by market cap ($156.6 million vs $153.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | TARA |
|---|---|---|
| Share price | $3.22 | $2.65 |
| Market cap | $153.75M | $156.60M |
| 1-day change | -1.53% | +2.32% |
| YTD return | -19.90% | -50.28% |
| 1-year return | +13.78% | -47.73% |
| 5-year return | -70.19% | -61.26% |
| EPS (TTM) | $-35.62 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $7.82 |
| 52-week low | $2.24 | $2.51 |
| Distance from 52-week high | -74.16% | -66.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +220.81% | +870.19% |
| Average volume | 183.63K | 804.10K |
| Shares outstanding | 47.75M | 59.10M |
| Employees | 7 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed TARA by 61.5 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
NERV vs TARA FAQ
Which is bigger, Minerva Neurosciences or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $156.60M compared with $153.75M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or TARA?
NERV returned +13.78% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Protara Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Minerva Neurosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Protara Therapeutics.